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SUMMARY AT A GLANCE : This study compared perceived sleep disruption due to 
breathlessness and sleep quality during four days of regular low dose (20mg sustained release) 
oral morphine versus placebo in elderly participants with refractory breathlessness. This is the 
first study to raise the possibility that low dose morphine to reduce breathlessness may also 
improve sleep quality and vice versa. 
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ABSTRACT 
Background and Objectives: The management of chronic refractory breathlessness is one of 
the indications for regular low dose (≤30mg/24hrs) oral sustained release morphine. Morphine 
may disrupt sleep in some conditions and improve sleep quality in others. This study aimed to 
determine any signal of regular, low dose morphine on perceived sleep disruption due to 
breathlessness and perceived sleep quality. 
Methods: This is a secondary analysis of data from 38 participants with refractory 
breathlessness (30 male; 33 with COPD) aged 76±0.9 years who completed a double-blind, 
randomised, placebo-controlled, cross-over study in which they received 20mg oral sustained 
release morphine daily and placebo for 4 days each. Participant ratings of sleep disruption due 
to breathlessness and perceived sleep quality were obtained daily throughout the 8-day trial. 
Results: Perceived sleep disruption due to breathlessness over the 4 day period ranged between 
13-32% of participants for placebo and 13-26% for morphine, decreasing by each day of the 
study during the morphine arm. Most participants reported “very good” or “quite good” sleep 
throughout the trial and were less likely to perceive poor sleep quality during the morphine arm 
(Odds Ratio=0.55, 95% Confidence Interval 0.34-0.88, p=0.01). Participants who reported 
decreased breathlessness during the 4 days on morphine were also likely to report improved 
sleep quality with morphine (p=0.039). 
Conclusions: Four days of low dose morphine improved perceived sleep quality in elderly 
participants with refractory breathlessness. Regular low dose morphine targeted to reduce 
refractory breathlessness may yield associated benefits by reducing sleep disruption and 
improving sleep quality. 
Keywords: Opioids, COPD, Sleep-disordered breathing, Sleepiness, Dyspnoea, Controlled 
clinical trials. 
Short Title: Morphine, sleep quality & breathlessness
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INTRODUCTION 
Refractory breathlessness is a debilitating consequence of cardiopulmonary disease. 
Treatment of refractory breathlessness is of major importance yet effective treatment options 
are limited.  Regular, daily, low dose oral sustained release morphine (≤30mg) is clinically 
effective and safe in reducing symptoms of breathlessness in people with refractory 
breathlessness.1-3 However, the mechanisms by which morphine reduces breathlessness are 
incompletely understood and are likely to be multifactorial. Similarly, the effects of regular, 
low dose morphine on other key outcomes including sleep quality, which may contribute to 
changes in perceived breathlessness with morphine, remain largely unknown. 
 Although morphine has been traditionally prescribed for pain management, its effects on 
sleep quality and sleep disturbance are unclear. Rather than sleep promotion, acute 
administration of variable and often quite high doses of morphine (administered orally, 
intramuscularly and intravenously) in healthy individuals can increase brief awakenings 
(arousals) and reduce slow wave and rapid eye movement (REM) sleep.4-6 These observations 
are supported by recent mechanistic studies in rats.7  
At doses in excess of 30mg/day, morphine may contribute to sleep-related breathing 
disturbances, particularly central sleep apnoea by a combination of sedation and a reduction in 
central and peripheral chemoreflex responsiveness.8-13 However, the majority of prior studies 
in this area have been cross sectional. This is problematic as many patients who are prescribed 
morphine are taking other centrally acting medications and their co-morbid conditions may also 
contribute to sleep disruption.14 As such, there have been very few appropriately designed 
studies to systematically examine the effect of morphine on sleep quality,15 particularly at 
relatively low doses in steady state and in clinically relevant populations such as people with 
increased respiratory drive due to pain or chronic refractory breathlessness.16  
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Conversely, while there is the potential for morphine to disrupt sleep, morphine may actually 
improve sleep quality and related symptoms in certain patient populations. For example, sleep 
disruption is common in chronic pain and poor sleep worsens pain perception.17, 18 When 
administered at doses that do not cause respiratory depression, morphine can improve sleep and 
pain in people experiencing chronic pain.19, 20 Recent advances in the understanding of sleep-
disordered breathing clearly identify marked heterogeneity in the underlying pathophysiology 
and the response to opioids.21-23  
Some central nervous system depressants, including preliminary findings with morphine, 
that target non-anatomical causes of sleep-disordered breathing can reduce disease severity and 
improve overnight oxygenation in certain patients.22-24 Thus, morphine may improve 
respiratory related outcomes in some patients and worsen outcomes in others. Given that the 
use of morphine and other opioids continues to increase, in conjunction with concerns about 
serious harms,25-29 it is of critical importance to determine if clinically relevant doses of 
morphine for chronic refractory breathlessness disrupt sleep and, if so, in which patient 
populations.  
In this phase II study we examine the effects of four consecutive days of regular low dose 
morphine (20mg oral sustained release each morning) compared to placebo in a double-blind, 
randomised, cross-over study on perceived sleep disruption due to breathlessness and perceived 
sleep quality in a clinically relevant population of patients with chronic refractory 




The data reported in this pilot study are a secondary analysis of 48 participants with chronic 
refractory breathlessness at rest or on minimal exertion, 38 of whom completed a randomised, 
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double-blind placebo controlled crossover trial to investigate the effects of morphine on 
breathlessness.1 Perceived sleep disruption due to breathlessness at day 4 during placebo and 
morphine was reported in the parent study.1 However, none of the other data in the current study 
has been reported previously. Participants had no history of recent opioid use, no prior adverse 
reaction to opioids, and no history of substance misuse. All participants’ specialists confirmed 
that reversible factors contributing to breathlessness were optimally treated prior to enrolment. 
A patient flow diagram is provided in the parent study.1 Written informed consent to participate 
in the study was obtained from each participant. The protocol was approved by the Repatriation 
General Hospital Research Ethics Committee and was registered on the Australian and New 
Zealand Clinical Trials Registry (ACTRN12607000075482).  
Protocol and Measures of Sleepiness 
Participants were studied over eight consecutive days according to a double-blind, 
randomised, cross-over design.1 Participants were randomised to receive either four days of 
placebo followed by four days of morphine (20mg oral sustained release morphine, Kapanol, 
Glaxo Smith Kline, Australia) or vice versa. The study medication was taken each morning. 
There was no wash out period. Two questions relating to perceived sleep quality were assessed 
daily using patient diary report throughout the trial. Study nurses visited on days 4 and 8 and 
telephoned on days 2 and 6 to ensure safety, and optimise data collection and study protocol 
adherence. The specific sleep-related questions assessed throughout the trial were:  
1) “Was your sleep disturbed by your breathlessness?” (hereon defined as: “sleep disruption 
due to breathlessness”; yes/no); and 
2) “How was your sleep last night?” (hereon defined as “sleep quality”; four-point scale 
where 1=very good, 2=quite good, 3=poor, and 4=no sleep).  




Generalized Estimating Equations (GEE) were used to take into account the repeated 
measures design and correlation between subjects. The model specification was binary logistic 
(sleep disruption due to breathlessness) or ordinal logistic (sleep quality). The factors included 
in the models were treatment (morphine vs. placebo), time (in days), and treatment by time 
interaction effects. An interaction term between treatment and intervention order was also 
included to test for potential carry over effects and was reported separately in the text. Kruskal-
Wallis one way analysis of variance on ranks was used to compare changes in breathlessness 
(VAS) and sleep quality from day 1 to day 4 during the morphine arm separated into three 
groups (1. reduction, 2. no change and 3. increase in sleep quality from day 1 to day 4). Post 
hoc comparisons were performed using Dunns’ Method. Analyses were conducted using SPSS 




The mean age of the study participants (30 males) was 76±0.9 years. Thirty three of the 38 
participants who completed all eight days of the trial had chronic obstructive pulmonary disease 
(COPD), presenting with breathlessness at rest or on minimal exertion. The remaining five 
participants with breathlessness had cancer, motor neurone disease, or restrictive lung disease. 
According to the Eastern Cooperative Oncology Group scale, 71% of the participants were 
severely restricted (ECOG >2). Twenty eight of the participants were on supplemental oxygen 
throughout the trial. Twenty of the 38 participants received placebo for the first four days and 
18 received morphine for the first four days. Further details of the participant characteristics are 
reported in the parent study1. Results from the GEE regression models are presented in Table 
1. 
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Sleep Disruption due to Breathlessness 
The percentage of participants who reported sleep disruption due to breathlessness over the 
4 day period ranged between 13% and 32% for placebo and 13% and 26% for morphine (Figure 
1). The GEE model shows that participants using morphine on day one of treatment (regardless 
of the allocation order) experienced higher odds of perceived sleep disruption due to 
breathlessness compared to placebo but the odds decreased by 21% for each additional day of 
treatment compared to the placebo group as indicated by treatment*time interaction (Table 1). 
Conversely, the opposite effect was noted during the placebo arm such that the odds of 
perceived sleep disruption due to breathlessness increased by 27% for each additional day on 
placebo (Figure 1). There were no carry over effects for sleep disruption due to breathlessness 
(p= 0.69). 
Sleep Quality 
Throughout the trial most participants rated their sleep quality as “quite good” during both 
arms, while the “no sleep” category was used only once and was therefore collapsed with the 
“poor” category (Figure 2). There was no significant treatment*time interaction effect 
(interaction term OR=0.98, 95% CI=0.70-1.36 p=0.89). Thus, the interaction term was omitted 
from the final GEE model. During the morphine arm, participants were less likely to experience 
poor sleep quality during the morphine arm (OR=0.55; 95% CI=0.34-0.88; p=0.01; Table 1). 
There were no carry over effects for sleep quality (p=0.71). 
There was significant group effect (p=0.039) for change in breathlessness versus change in 
sleep quality from day 1 to day 4 during the morphine condition (Figure 3). Specifically, the 
group who reported an improvement in sleep quality from day 1 to day 4 during the morphine 
arm had a significantly larger reduction in breathlessness compared to the group who reported 




Given the growing evidence base for regular low dose morphine (≤30mg oral sustained 
release) to treat refractory breathlessness, and its potential to cause impairment and serious 
harm,25-32 it is crucial to accurately determine the effects of clinically relevant repeat doses of 
morphine on sleep. The findings of the current phase II pilot study indicate that four days of 
sustained release morphine, at a dose sufficient to reduce symptoms of breathlessness by a 
clinically meaningful degree,1, 3, 33 improves perceived sleep quality in this elderly population 
of patients with refractory breathlessness.  
These findings are intriguing as they suggest that rather than impairing sleep, low doses of 
morphine targeted to the underlying condition (in this case breathlessness) may actually 
improve overall sleep quality and could contribute to improvements in symptom perception 
relating to the underlying condition. Although pain perception was not the focus of the current 
investigation, the proposed scenario for sleep and breathlessness is consistent with the 
purported bi-directional relationship in patients suffering from pain in whom strategies to 
improve pain symptoms (including morphine) can improve sleep, and improved sleep may 
facilitate further reductions in perceived pain and vice versa.17-20  
Recent preliminary findings indicate that a single 30mg sustained release oral dose of 
morphine does not worsen obstructive sleep apnoea as measured by the apnoea/hypopnea index 
and can actually improve overnight hypoxemia in certain cases.22, 23 These effects are related to 
changes in ventilatory control and blood morphine concentration, both of which vary greatly 
between individuals.21-23 Similarly, dihydrocodeine reduces peripheral chemosensitivity and 
oscillatory breathing in patients with chronic heart failure.34 However, patients with COPD who 
are hypoxic awake and also have sleep-disordered breathing may be particularly vulnerable to 
severe overnight hypoxemia especially during REM sleep.35 Thus, determining the effects of 
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clinically relevant doses of morphine on sleep-disordered breathing and overnight oxygenation 
in patients with COPD is a priority. 
Ultimately, achieving the balance between optimal morphine dose to obtain therapeutic 
benefit for the underlying condition without disrupting sleep nor affecting daytime function 
will be crucial. While further data are clearly required, the current findings are consistent with 
ongoing work in pain that suggest that regular low doses of morphine that reduce symptoms of 
breathlessness,1, 36 may also yield improvements in sleep quality which could contribute, at least 
in part, to the observed therapeutic benefit and vice versa. Conversely, in those who experience 
a worsening of sleep quality with morphine, a reduction in morphine dose or medication 
cessation should be considered and investigation and treatment of any potential sleep disorder 
should be undertaken, if clinically warranted.  
Methodological Considerations and Recommendations for Future Studies 
Strengths of the current approach include the use of rigorous clinical trial design and 
standardised assessments over several consecutive days including steady-state which is reached 
in 36 hours using this drug delivery system.  
However, this pilot study has several limitations. Firstly, measures of sleep disruption and 
sleep quality were subjective and were acquired using non-validated assessment tools. Sleep 
studies were also not performed. Nonetheless, the assessment tools have face validity and given 
the paucity of data in this area, the current findings provide novel insights to inform larger 
future intervention trials in which objective measures of sleep and daytime function should be 
incorporated prospectively.  
Perceived sleep quality was also quite high in the current study. Thus, it will also be 
important to examine the effects of morphine in people who specifically report poor sleep 
quality in future studies. 
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The goal of the parent study was to assess the effects of low dose morphine on breathlessness 
in the steady-state (day 4).1 This negated the need for a wash out period. We did not find any 
evidence for carry over effects in the sleep parameters assessed in the current study. Thus, the 
lack of a wash out period is unlikely to have influenced the current findings. Indeed, the new 
findings reported in the current pilot study showing gradual reductions in sleep disruption due 
to breathlessness over 4 days during the morphine arm with corresponding reductions in 
breathlessness, expand upon and are consistent with the prior findings reported in the parent 
study of reduced sleep disruption due to breathlessness with low dose morphine versus placebo 
in steady-state (day 4).1 Nonetheless, future trials that incorporate additional sleep and alertness 
measures should include a wash out period or a parallel arm design to avoid any potential carry 
over effects. 
Consistent with a biphasic response, perceived sleep disruption due to breathlessness was 
relatively high on night one of morphine compared to placebo but steadily decreased thereafter. 
This pattern suggests that acute sleep disruption may mediate night one effects, at least in part. 
However, the steady decrease thereafter in the absence of a plateau highlights the clear need to 
follow patients over time as there is potential for additional benefit beyond the four days tested 
in the current protocol. Thus, these novel findings challenge previous notions and warrant 
further investigation. 
Summary of Future Research Directions 
The current findings pave the way for future studies to explore these proposed relationships 
in the clinically relevant population of COPD in whom chronic refractory breathlessness at rest 
or on minimal exertion and sleep disturbances are common.35, 37 Key priorities for future work 
will be to incorporate: 1) formal sleep studies, 2) validated and more detailed assessments of 
sleep, overnight oxygenation and daytime alertness, 3) a longer intervention and assessment 
period in a larger cohort of participants in whom disease severity and other potential 
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confounding factors (e.g. nocturnal O2 therapy, CPAP and other centrally acting medications) 
are carefully codified and 4) a wash-out period or parallel study design.  
Conclusions 
In summary, the findings of this pilot study provide insight into the potential effects of 
clinical use of regular low dose morphine on perceived sleep quality in people with chronic 
refractory breathlessness. A dose of 20mg of sustained release oral morphine each morning 
reduced sleep disruption due to breathlessness in a time dependent manner and improved 
perceived sleep quality. Given the high rates of morphine use and potential for serious harm, 
these findings add to the data on safety of this clinical intervention. In addition, these findings 
raise the possibility that reductions in perceived breathlessness with morphine may be mediated, 
at least in part, by  improvement in sleep quality or vice versa.  
 
ACKNOWLEDGEMENTS 
The authors would like to thank all of the participants in this study who gave their time and 
energy despite the problems that they were encountering. RTM and DJE are supported by a 
National Health and Medical Research Council (NHMRC) of Australia NeuroSleep Centre for 
Research Excellence Grant (1060992) and DJE holds a NHMRC RD Wright Biomedical 
Fellowship (1049814). DCC has also received funding support from the NHMRC of Australia. 
APA’s salary was provided through a clinical scientist development award from the Doris Duke 
Charitable Foundation of New York, NY, USA. Funds for the conduct of the study were 










1. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double 
blind, placebo controlled crossover trial of sustained release morphine for the management 
of refractory dyspnoea. BMJ. 2003;327:523-8. 
2. Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, et al. Once-daily opioids 
for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom 
Manage. 2011;42:388-99. 
3. Ekstrom MP, Abernethy AP, Currow DC. The management of chronic breathlessness in 
patients with advanced and terminal illness. BMJ. 2015;349:g7617. 
4. Kay DC, Eisenstein RB, Jasinski DR. Morphine effects on human REM state, waking state 
and NREM sleep. Psychopharmacologia. 1969;14:404-16. 
5. Dimsdale JE, Norman D, DeJardin D, Wallace MS. The effect of opioids on sleep 
architecture. J Clin Sleep Med. 2007;3:33-6. 
6. Shaw IR, Lavigne G, Mayer P, Choiniere M. Acute intravenous administration of morphine 
perturbs sleep architecture in healthy pain-free young adults: a preliminary study. Sleep. 
2005;28:677-82. 
7. Wang Q, Yue XF, Qu WM, Tan R, Zheng P, Urade Y, et al. Morphine inhibits sleep-
promoting neurons in the ventrolateral preoptic area via mu receptors and induces 
wakefulness in rats. Neuropsychopharmacology. 2013;38:791-801. 
8. Eckert DJ, Jordan AS, Merchia P, Malhotra A. Central sleep apnea: Pathophysiology and 
treatment. Chest. 2007;131:595-607. 
9. Javaheri S, Harris N, Howard J, Chung E. Adaptive servoventilation for treatment of 
opioid-associated central sleep apnea. J Clin Sleep Med. 2014;10:637-43. 
10. Javaheri S, Randerath WJ. Opioid-Induced Central Sleep Apnea: Mechanisms and 
Therapies. Sleep Med Clinics. 2014;9:49–56. 
 
11. Martins RT, Eckert DJ. Central sleep apnea due to other medical disorders. Sleep Med 
Clinics. 2014;9:57–67. 
12. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment 
of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of 
randomized controlled trials. JAMA. 2005;293:3043-52. 
13. Rose AR, Catcheside PG, McEvoy RD, Paul D, Kapur D, Peak E, et al. Sleep disordered 
breathing and chronic respiratory failure in patients with chronic pain on long term opioid 
therapy. J Clin Sleep Med. 2014;10:847-52. 
14. Mador MJ, Henderson J. Effect of opioids on sleep and breathing in chronic pain patients. 
J Clin Sleep Med. 2014;10:853-4. 
15. Mercadante S, Vellucci R, Cuomo A, Adile C, Cortegiani A, Valle A, et al. Long-term 
efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. 
Support Care Cancer. 2015;23:1349-54. 
16. Jolley CJ, Luo YM, Steier J, Reilly C, Seymour J, Lunt A, et al. Neural respiratory drive 
in healthy subjects and in COPD. Eur Respir J. 2009;33:289-97. 
17. Alsaadi SM, McAuley JH, Hush JM, Lo S, Bartlett DJ, Grunstein RR, et al. The 
bidirectional relationship between pain intensity and sleep disturbance/quality in patients 
with low back pain. Clin J Pain. 2014;30:755-65. 
18. Alsaadi SM, McAuley JH, Hush JM, Lo S, Lin CW, Williams CM, et al. Poor sleep quality 
is strongly associated with subsequent pain intensity in patients with acute low back pain. 
Arthritis Rheumatol. 2014;66:1388-94. 
19. Brennan MJ, Lieberman JA, 3rd. Sleep disturbances in patients with chronic pain: 
effectively managing opioid analgesia to improve outcomes. Curr Med Res Opin. 
2009;25:1045-55. 
 
20. Rosenthal M, Moore P, Groves E, Iwan T, Schlosser LG, Dziewanowska Z, et al. Sleep 
improves when patients with chronic OA pain are managed with morning dosing of once 
a day extended-release morphine sulfate (AVINZA): findings from a pilot study. J Opioid 
Manag. 2007;3:145-54. 
21. Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining phenotypic causes of 
obstructive sleep apnea. Identification of novel therapeutic targets. Am J Respir Crit Care 
Med. 2013;188:996-1004. 
22. Wang D, Eckert DJ, Grunstein RR. Drug effects on ventilatory control and upper airway 
physiology related to sleep apnea. Respir Physiol Neurobiol. 2013;188:257-66. 
23. Wang D, Somogyi AA, Yee BJ, Wong KK, Kaur J, Wrigley PJ, et al. The effects of a single 
mild dose of morphine on chemoreflexes and breathing in obstructive sleep apnea. Respir 
Physiol Neurobiol. 2013;185:526-32. 
24. Eckert DJ, Owens RL, Kehlmann GB, Wellman A, Rahangdale S, Yim-Yeh S, et al. 
Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea 
index in obstructive sleep apnoea patients with a low arousal threshold [Accelerated 
Publication]. Clin Sci (Lond). 2011;120:505-14. 
25. Degenhardt L, Black E, Breen C, Bruno R, Kinner S, Roxburgh A, et al. Trends in 
morphine prescriptions, illicit morphine use and associated harms among regular injecting 
drug users in Australia. Drug Alcohol Rev. 2006;25:403-12. 
26. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363:1981-5. 
27. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, et al. 
Association between opioid prescribing patterns and opioid overdose-related deaths. 
JAMA. 2011;305:1315-21. 
 
28. Ekstrom MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of 
benzodiazepines and opioids in very severe respiratory disease: national prospective study. 
BMJ. 2014;348:g445. 
29. Gwira Baumblatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-
risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern 
Med. 2014;174:796-801. 
30. Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E. Driving ability in cancer patients 
receiving long-term morphine analgesia. Lancet. 1995;346:667-70. 
31. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant 
patients impaired in driving-related skills? A structured evidence-based review. J Pain 
Symptom Manage. 2003;25:559-77. 
32. Mailis-Gagnon A, Lakha SF, Furlan A, Nicholson K, Yegneswaran B, Sabatowski R. 
Systematic review of the quality and generalizability of studies on the effects of opioids on 
driving and cognitive/psychomotor performance. Clin J Pain. 2012;28:542-55. 
33. Johnson MJ, Bland JM, Oxberry SG, Abernethy AP, Currow DC. Clinically important 
differences in the intensity of chronic refractory breathlessness. J Pain Symptom Manage. 
2013;46:957-63. 
34. Ponikowski P, Anker SD, Chua TP, Francis D, Banasiak W, Poole-Wilson PA, et al. 
Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: 
clinical implications and role of augmented peripheral chemosensitivity. Circulation. 
1999;100:2418-24. 
35. Weitzenblum E, Chaouat A, Kessler R, Canuet M. Overlap syndrome: obstructive sleep 
apnea in patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc. 
2008;5:237-41. 
 
36. Rocker GM, Simpson AC, Horton R, Sinuff T, Demmons J, Hernandez P, et al. Opioid 
therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary 
disease: patients' experiences and outcomes. CMAJ Open. 2013;1:E27-36. 
37. Elkington H, White P, Addington-Hall J, Higgs R, Edmonds P. The healthcare needs of 
chronic obstructive pulmonary disease patients in the last year of life. Palliat Med. 
2005;19:485-91. 
 
Table 1.  
Sleep-related outcome measures in a placebo controlled crossover trial of regular low dose 
morphine (20mg oral sustained release daily) versus placebo in participants with chronic 
refractory dyspnoea, N=38. 
 
 




GEE Model Binary logistic Ordinal logistic  
Covariates OR (95% CI) p-value OR (95% CI) p-value 
     
Morphine vs. placebo 3.23 (1.37-7.6) <0.01 0.55 (0.34-0.88) 0.01 
Time (in days) 1.35 (0.94-1.7) <0.01 0.91 (0.78-1.06) 0.24 
Morphine vs. placebo and 
time interaction 0.58 (0.41-0.84) <0.01 - - 
 
GEE= Generalized Estimating Equations, OR= Odds Ratio, CI= Confidence Interval. Refer to 





Figure 1. Count of participants who reported sleep disruption due to breathlessness during the 
4 days of 20mg oral sustained release morphine and placebo, N=38. There was a significant 
treatment*time interaction effect such that fewer participants reported breathless related sleep 
disruption from days 1-4 on morphine whereas the opposite effect was observed during placebo. 





Figure 2. Count of perceived prior night sleep quality during the 4 days of 20mg oral sustained 
release morphine and placebo, N=38. There was a significant effect of treatment such that 
participants were less likely to report higher levels of the Likert scale compared to placebo, 
reflecting lower odds of experiencing poor sleep quality during the morphine arm. 





Figure 3. Change (∆) in breathlessness (visual analogue scale) from day 1 to 4 during the 
morphine arm according to whether participants reported no change (n=20), worsening (n=7) 
or improvement (n=11) in sleep quality during the same period. There was a significant group 
effect (p=0.039). * indicates a significant difference between groups (P<0.05). Box plots 
represent median values and 25th and 75th centiles. Whiskers indicate 5th and 95th centiles. Open 
circles represent data that falls outside these ranges.  
 
 
 
 
